Mauro Cancian

ORCID: 0000-0003-2246-9144 · 3 papers in corpus
nonrandomized-trial 2025
Effective long-term prophylaxis with lanadelumab in adolescents with hereditary angioedema: EMPOWER/ENABLE
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology ·doi:10.1111/pai.70072

BACKGROUND: Symptoms of hereditary angioedema (HAE) typically first present during childhood, but the frequency/severity of attacks often increases at puberty. Real-world data on long-term HAE prophylaxis in adolescents are limited. We repo…

guideline 2025
Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and Treatment
Clinical reviews in allergy & immunology ·doi:10.1007/s12016-025-09027-4

Hereditary angioedema (HAE) has been recognized for almost 150 years. The newest form of HAE, where C1 inhibitor levels are normal (HAE-nC1INH), was first described in 2000. Over the last two decades, new types of apparent non-mast cell-med…

observational 2023
The impact of puberty on the onset, frequency, location, and severity of attacks in hereditary angioedema due to C1-inhibitor deficiency: A survey from the Italian Network for Hereditary and Acquired Angioedema (ITACA)
Frontiers in pediatrics ·doi:10.3389/fped.2023.1141073

INTRODUCTION: Hereditary angioedema due to C1-inhibitor deficiency is influenced by hormonal factors, with a more severe course of disease in women. Our study aims to deepen the impact of puberty on onset, frequency, location and severity o…